The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics

Social Studies of Science

Volumn 33, Issue 3, 2003, Pages 327-364

  Hedgecoe, Adam ^a   Martin, Paul ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bioethics; Biotechnology; Expectations; Genetics; Genomics; Pharmaceutical

Indexed keywords

BIOTECHNOLOGY; CONFERENCE PAPER; DRUG THERAPY; HISTORY; PHARMACOGENETICS;

BIOTECHNOLOGY; DRUG THERAPY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; PHARMACOGENETICS;

EID: 0242330670     PISSN: 03063127     EISSN: None     Source Type: Journal    
DOI: 10.1177/03063127030333002     Document Type: Conference Paper

References (129)

1. Abraham, John (1997) 'The Science and Politics of Medicines Regulation', in Elston (1997): 151-82.
2. Akhtar, Saghir (2002) 'Pharmacogenomics: Are Pharmacists Ready for Genotyped Prescribing?', The Pharmaceutical Journal 268 (2 March): 296-99.
3. Ameen, M., Catherine H. Smith, and Jonathon N.W.N. Barker (2002) 'Pharmacogenetics in Clinical Dermatology', British Journal of Dermatology 146(1) (January): 2-6.
4. Anderlik, Mary and Mark Rothstein (2000) 'Privacy and Confidentiality of Genetic Information: What Rules for the New Science?', Annual Review of Genomics and Human Genetics 2: 401-33.
5. Anderson, Wayne, Craig Fitzgerald and Penelope Manasco (1999) 'Current and Future Applications of Pharmacogenomics', New Horizons: Science and Practice of Acute Medicine 7(2) (April): 262-69.
6. Arledge, Teresa, Andrew Freeman, Julian Arbuckle, Michael Mosteller and Penelope Manasco (2000) 'Applications of Pharmacogenetics to Drug Development: The Glaxo Wellcome Experience', Drug Metabolism Reviews 32(3-4): 387-94.
7. Arranz, Maria J., J. Munro, J. Birkett, A. Bolonna, D. Mancama, M. Sodhi, K. Lesch, J. Meyer, P. Sham, D. Collier, R. Murray and R. Kerwin (2000) 'Pharmacogenetic Prediction of Clozapine Response', The Lancet 355 (6 May): 1615-16.
8. Bell, John (1997) 'Genetics of Common Disease', Philosophical Transactions of the Royal Society of London 352: 1051-55.
9. Bell, John (1998) 'The New Genetics and Clinical Practice', British Medical Journal 316: 618-20.
10. Bijker, Wiebe (1995) Of Bicycles, Bakelites and Bulbs: Towards a Theory of Sociotechnical Change (Cambridge, MA: MIT Press).
11. Bijker, Wiebe, Thomas Hughes and Trevor Pinch (1987) The Social Construction of Technological Systems (Cambridge, MA: MIT Press).
12. Blume, Stuart (1992) Insight and Industry: on the Dynamics of Technological Change in Medicine (Cambridge, MA: MIT Press).
13. Broder, Sam, Arthur Caplan and William Evans (2002) 'Therapeutic Horizons -The Human Genome', Journal of the American Pharmaceutical Association 42(5 Suppl 1): S22-23.
14. Brown, Nik, Brian Rappert and Andrew Webster (eds) (2000) Contested Futures: A Sociology of Prospective Techno-science (Aldershot: Ashgate Press).
15. Callahan, Daniel (2001) 'Doing Good and Doing Well', The Hastings Center Report 31(2): 19-21.
16. Callon, Michel (1987) 'Society in the Making: The Study of Technology as a Tool for Sociological Analysis', in Bijker et al. (1987): 83-103.
17. Cantor, Charles (1999) 'Pharmacogenetics Become Pharmacogenomics: Wake Up and Get Ready', Molecular Diagnosis 4(4) (December): 287-88.
18. Cardon, Lou, Rammana Idury, Timothy Harris, John Witte and Robert Elston (2000) 'Testing Drug Response in the Presence of Genetic Information: Sampling Issues for Clinical Trials', Pharmacogenetics 10: 503-10.
19. Carr, G. (1998) 'Survey: The Pharmaceutical Industry', The Economist 345 (21 February): 1-16 of supplement.
20. Carroll, A. and C. Coleman (2001) 'Closing the Gaps in Genetics Legislation and Policy: A Report by the New York State Task Force on Life and the Law', Genetic Testing 5(4) (Winter): 275-80.
21. Chadwick, Ruth (1999) 'Criteria for Genetic Screening: The Impact of Pharmaceutical Research', Monash Bioethics Review 18(1) (January): 22-26.
22. Chamberlain, John and Pieter Joubert (2001) 'Opportunities and Strategies for Introducing Pharmacogenetics into Early Drug Development', Drug Development Today 6(11) June): 569-74.
23. Clarke, Angus, Veronica English, Hilary Harris and Frank Wells (2001) 'Report on Ethical Considerations', International Journal of Pharmaceutical Medicine 15: 89-94.
24. Cobleigh, Melody, Charles Vogel, Debu Tripathy, Nicholas Robert, Susy Scholl, Louis Fehrenbacher, Janet Wolter, Virginia Paton, Steven Shak, Gracie Lieberman and Dennis Slamon (1999) 'Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women who have HER2-overexpressing Metastatic Breast Cancer that has Progressed after Chemotherapy for Metastatic Disease', Journal of Clinical Oncology 17: 2639-48.
25. Cookson, Clive (1997) 'Personalised Treatment', Financial Times (12 August 1997): 10.
26. Coombs, Rod, Ken Green, Albert Richards and Vivien Walsh (2001) Technology and the Market: Demand, Users and Innovation (Cheltenham: Edward Elgar).
27. Corrigan, Oonagh (2002) 'A Risky Business: The Detection of Adverse Drug Reactions in Clinical Trials and Post-Marketing Exercises', Social Science and Medicine 55: 497-507.
28. Davis, Alison and Rochelle Long (2001) 'Pharmacogenetics Research Network and Knowledge Base: 1st Annual Scientific Meeting', Pharmacogenomics 2(3) (August): 285-89.
29. De Laat, Bastiaan (2000) 'Scripts for the Future: Using Innovation Studies to Design Foresight Tools', in Brown et al. (2000): 175-208.
30. Department of Health (2000) Harnessing the Potential of Gene Science: A Strategy for the DH (London: Strategy and Planning, DoH).
31. Deuten, J. Jasper and Arie Rip (2000) 'The Narrative Shaping of a Product Creation Process' in Brown et al. (2000): 65-86.
32. Dhanda, Rahul (2002) Guiding Icarus: Merging Bioethics with Corporate Interests (New York: John Wiley & Sons).
33. Drazen, Jeffrey, ChandriYandava, Louise Dube, Natalie Szczerback, Richard Hippensteel, Antonino Pillari, Elliot Israel, Nicholas Schork, Eric Silverman, David Katz and Jeffrey Drajesk (1999) Pharmacogenetic Association between ALOX5 Promoter Gnotype and the Response to Anti-Asthma Treatment', Nature Genetics 22: 168-70.
34. Elliott, Carl (2001) 'Pharma Buys a Conscience', The American Prospect Online 12(17), September 24(96)October 8, www.prospect.org/ Accessed 27 January 2003.
35. Elston, Mary (ed.) (1997) The Sociology of Medical Science and Technology (Oxford: Blackwell).
36. Emilien, G., M. Ponchon, C. Caldas, O. Isacson, and J.M. Maloteaux (2000) 'Impact of Genomics on Drug Discovery and Clinical Medicine', Quarterly Journal of Medicine 93(7): 391-423.
37. Ensom, Mary, Thomas Chang and Payal Patel (2001) 'Pharmacogenetics: The Therapeutic Drug Monitoring of the Future', Clinical Pharmacokinetics 40(11): 783-802.
38. Evans, William and Mary Relling (1999) 'Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics', Science 286 (15 October): 487-91.
39. Foster, Morris W., R. Sharp and J. Mulvihill (2001) 'Pharmacogenetics, Race and Ethnicity: Social Identifiers and Individualized Medical Care', Therapeutic Drug Monitoring 23(3): 232-38.
40. Francke, Uta (2001) 'The Human Genome Project: Implications for the Endocrinologist', Journal of Pediatric Endocrinology and Metabolism 14 Suppl 6: 1395-408.
41. Fujiki, Norio (2000) 'A Biography and Bibliography: The Recent Trends in Bioethics and Medical Genetics in Japan (Part II)', Law and Human Genome Review (13): 183-210.
42. Ginsburg, Geoffry and Jeanette McCarthy (2001) 'Personalized Medicine: Revolutionizing Drug Discovery and Patient Care', Trends in Biotechnology 19(12) (12 December): 491-99.
43. Glaser, Vicki (1998) 'Pharmacogenomics: Laying the Foundation for Prescriptive Medicine', Genetic Engineering News 1 January 1998: 1, 9, 31 and 39.
44. Gonzalez, Frank J. et al. (1988) 'Characterization of the Common Genetic Defect in Humans Deficient in Debrisoquine Metabolism' Nature 331 (6155) (4 February): 442-46.
45. Grin, John and Armin Grunwald (2000) Vision Assessment: Shaping Technology in 21st Century Society (Springer: Berlin).
46. Guice, John (1999) 'Designing the Future: The Culture of New Trends in Science and Technology', Research Policy 28: 81-98.
47. Haseltine, William (1998) 'Not Quite Pharmacogenetics' letter, Nature Biotechnology 16: 1295.
48. Hedgecoe, Adam (2002) 'Reinventing Diabetes: Classification, Division and the Geneticization of Disease', New Genetics and Society 21 (1) (April): 7-27.
49. Hedgecoe, Adam (2003) 'Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics', Science, Technology and Human Values 28(4) (in press).
50. Hinde, Annabel (2000) 'Evolution, not Revolution', Trends in Biotechnology 18(6): 230-31.
51. Housman, David and Fred Ledley (1998) 'Why Pharmacogenomics? Why Now?', Nature Biotechnology 16: 492-93.
52. Hughes, Thomas (1987) 'The evolution of Large Technical Systems', in Bijker et al. (1987): 51-82.
53. Ingelman-Sundberg, Magnus (2001) 'Pharmacogenetics: An Opportunity for a Safer and More Efficient Pharmacotherapy', Journal of Internal Medicine 250: 186-200.
54. Issa, Amalia (2000) 'Ethical Considerations in Clinical Pharmacogenomics Research', Trends in Pharmacological Science 21: 247-49.
55. Issa, Amalia (2002) 'Ethical Perspectives on Pharmacogenomic Profiling in the Drug Development Process', Nature Reviews Drug Discovery 1 (4) (April): 300-08.
56. Issa, Amalia and Edward Keyserlingk (2000) 'Apolipoprotein E Genotyping for Pharmacogenetic Purposes in Alzheimer's Disease: Emerging Ethical Issues', Canadian Journal of Psychiatry 45: 917-22.
57. Jazwinska, Elizabeth (2001) 'Exploiting Human Genetic Variation in Drug Discovery and Development', Drug Discovery Today 6(4) (February): 198-205.
58. Jones, Judith K. (2001) 'Pharmacogenetics and Pharmacoepidemiology', Pharmacoepidemiology and Drug Safety 10(5) (August/September): 457-61.
59. Kalow, Werner (1990) 'Pharmacogenetics: Past and Future', Life Sciences 47: 1385-97.
60. Kalow, Werner (2001) 'Pharmacogenetics in Perspective', Drug Metabolism and Disposition 29(4) (April): 468-70.
61. Kaplan, Jean-Claude and Claudine Junien (2000) 'Genomics and Medicine: An Anticipation. From Boolean Mendelian Genetics to Multifactorial Molecular Medicine', Comptes Rendus de l'Academie des Sciences (Paris) Series III 323(12) (December): 1167-74.
62. Kleyn, Patrick and Elliot Vesell (1998) 'Drug Variation as a Guide to Drug Development', Science 281 (18 September): 1820-21.
63. Kozma, Chahira (2001) 'Genetic Testing and Disease State Management', Managed Care Interface 14(11): 54-57.
64. Kreeger, Karen Young (2001) 'Scientific, Ethical Questions Temper Pharmacogenetics', The Scientist 15(12) (11 June): 32.
65. Krynetski, Eugene and William Evans (1999) 'Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-Methyltransferase Paradigm', Pharmaceutical Research 16: 342-49.
66. Kuivenhoven, Jan Albert, J. Wouter Jukema, Aeilko Zwinderman, Peter de Knijff, Ruth McPherson, Albert Bruschke, Kong Lie and John Kastelein (1998) 'The Role of a Common Variant of the CETP Gene in the Progression of Coronary Artherosclerosis', New England Journal of Medicine 338(2) (8 January): 86-93.
67. Kurth, Janice (2000) 'Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk', Drug Information Journal 34: 223-27.
68. Lavori, P., H. Krause-Steinrauf, M. Brophy, J. Buxbaum, J. Cockroft, D.R. Cox, L. Fiore, H. Greely, H. Greenberg, E. Holmes, L. Nelson and J. Sugarman (2002) 'Principles, Organization, and Operation of a DNA Bank for Clinical Trials: A Department of Veterans Affairs Cooperative Study' Controlled Clinical Trials 23(3) (June): 222-39.
69. Lea, Dale (2000) 'A New World View of Genetics Service Models', Online Journal of Issues in Nursing 5(3) (September): 5.
70. Lichter, Jay and Janice Kurth (1997) 'The Impact of Pharmacogenetics on the Future of Healthcare', Current Opinion in Biotechnology 8: 692-95.
71. Liggett, Stephen (2001) 'Pharmacogenetic Applications of the Human Genome Project', Nature Medicine 7(3): 281-83.
72. Lindpaintner, Klaus (1999) 'Genetics in Drug Discovery and Development: Challenge and Promise of Individualizing Treatment in Common Complex Disease', British Medical Bulletin 55(2): 471-91.
73. Lindpaintner, Klaus, Elizabeth Foot, Mark Caulfield and Ian Hall (2001) 'Pharmacogenetics: Focus on Pharmacodynamics', International Journal of Pharmaceutical Medicine 15: 74-82.
74. McCarthy, Alun (2000) 'Pharmacogenetics: Implications for Drug Development, Patients and Society', New Genetics and Society 19(2) (August): 135-43.
75. MacKenzie, Donald and Judy Wajcman (1999) The Social Shaping of Technology (Buckingham: Open University Press. Second edition).
76. McLeod, Howard L. and William E. Evans (2001) 'Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy', Annual Review of Pharmacology and Toxicology 41: 101-21.
77. Mancinelli, Laviero, Maureen Cronin and Wolfgang Sadée (2000) 'Pharmacogenomics: The Promise of Personalized Medicine', AAPS Pharmsci 2(1) (7 March), Article 4.
78. Marshall, Andrew (1997) 'Getting the Right Drug into the Right Patient', Nature Biotechnology 15: 1249-52.
79. Martin, Paul (1998) 'From Eugenics to Therapeutics: The Impact of Opposition on the Development of Gene Therapy in the USA', in Wheale et al. (1998): 139-58.
80. Martin, Paul (1999) 'Genes as Drugs: The Social Shaping of Gene Therapy and the Reconstruction of Genetic Disease', Sociology of Health and Illness 21: 517-38.
81. Martin, Paul (2001a) 'Genetic Governance: The Risks, Oversight and Regulation of Genetic Databases in the UK', New Genetics and Society 20(2) (August): 157-83.
82. Martin, Paul (2001b) 'Great Expectations: The Construction of Markets, Products and User Needs During the Early Development of Gene Therapy in the USA', in Coombs et al. (2001): 38-67.
83. Meyer, Urs (1990) 'Molecular Genetics and the Future of Pharmacogenetics', Pharmaceutical Therapies 46: 349-55.
84. Meyer, Urs (2000) 'Pharmacogenetics and Adverse Drug Reactions', The Lancet 356(11) (11 November): 1667-71.
85. Michael, Mike (2000) 'Futures of the Present: From Performance to Prehension', in Brown et al. (2000): 21-39.
86. Motulsky, Arno (1978) 'Bioethical Problems in Pharmacogenetics and Ecogenetics', Human Genetics Supplement 1: 185-92.
87. Moyses, Chris (1999) 'Pharmacogenetics, Genomics, Proteomics: The New Frontiers in Drug Development', International Journal of Pharmaceutical Medicine 13: 197-202.
88. Myers, Martin (2000) 'Use of Polymorphism Analysis Required Ethical Guidelines', British Medical Journal 321 (12 August) 12: 453.
89. Nebert, Daniel (1997) 'Pharmacogenetics: 65 Candles on the Cake', Pharmacogenetics 7: 435-40.
90. Nebert, Daniel and Eula Bingham (2001) 'Pharmacogenomics: Out of the Lab and Into the Community', Trends in Biotechnology 19(12): 519-23.
91. Norton, Ronald (2001) 'Clinical Pharmacogenomics: Applications in Pharmaceutical R&D', Drug Development Today 6(4) (February): 180-85.
92. Oestreicher, Paul (2001) '4th Annual Pharmacogenomics and Medicine Lectures', Pharmacogenomics 2(3) (August): 291-96.
93. Persidis, Aris (1998a) 'The Business of Pharmacogenomics', Nature Biotechnology 16: 209-10.
94. Persidis, Aris (1998b) 'Pharmacogenomics and Diagnostics', Nature Biotechnology 16: 791-92.
95. Persing, Brady and Denis Cheek (2000) 'Pharmacogenomics', Nursing Clinics of North America 35(4): 975-80.
96. Pfost, Daniel, Michael Boyce-Jacino and Denis Grant (2000) 'A SNPshot: Pharmacogenetics and the Future of Drug Therapy', Trends in Biotechnology 18: 334-38.
97. Phillips, Kathryn, David Veenstra, Eyal Oren, Jane Lee and Wolfgang Sadée (2001) 'Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review', Journal of the American Medical Association 286(18) (14 November): 2270-79.
98. Pinch, Trevor and Wiebe Bijker (1984) 'The Social Construction of Facts and Artefacts: Or How the Sociology of Science and the Sociology of Technology Might Benefit Each Other', Social Studies of Science 14: 399-441.
99. Poirier, Judes, Marie-Claude Delisle, Isabelle Aubert, Martin Farlow, Debmoi Lahir, Siu Hui, Phillipe Bertrand, Josephine Nalbantoglu, Brian Gilfix and Serge Gauthier (1995) 'Apolipoprotein E4 Allele as a Predictor of Cholinergic Deficits and Treatment Outcome in Alzheimer Disease', Proceedings of the National Academy of Sciences 92: 12260-64.
100. PriceWaterhouse Coopers (1999) Healthcast 2010: Smaller World, Bigger Expectation, www.pwchealth.com. Accessed 27 January 2003.
101. Regalado, Antonio (1999) 'Inventing the Pharmacogenomics Business', American Journal of Health System Pharmacy 56: 40-50.
102. Renegar, Gaile, Patricia Rieser and Penelope Manasco (2001 a) 'Family Consent and the Pursuit of Better Medicines Through Genetic Research', Journal of Continuing Education in the Health Professions 21(4) (Fall): 265-70.
103. Renegar, Gaile, Patricia Rieser and Penelope Manasco (2001b) 'Pharmacogenetics: The Rx Perspective', Expert Reviews in Molecular Diagnosis 1(3) (September): 255-63.
104. Richards, Tessa (2001) 'Three Views of Genetics: The Enthusiast, the Visionary and the Sceptic', British Medical Journal 322 (28 April): 1016-17.
105. Rioux, Patrice (2000) 'Clinical Trials in Pharmacogenetics and Pharmacogenomics: Methods and Applications', American Journal of Health System Pharmacy 57(9): 887-98.
106. Robertson, John (2001) 'Consent and Privacy in Pharmacogenetic Testing', Nature Genetics 28(3): 207-09.
107. Roses, Allen (2000a) 'Pharmacogenetics and the Practice of Medicine', Nature 405 (15 June): 857-65.
108. Roses, Allen (2000b) 'Pharmacogenetics and Future Drug Development and Delivery', The Lancet 355 (15 April): 1358-61.
109. Roses, Allen (2002) 'Genome-based Pharmacogenetics and the Pharmaceutical Industry', Nature Reviews Drug Discovery 1: 541-49.
110. Rothstein, Mark and Phyllis Griffin Epps (2001) 'Ethical and Legal Implications of Pharmacogenomics', Nature Reviews Genetics 2: 228-31.
111. Rusnak, James, Robert Kisabeth, David Herbert and Denis McNeil (2001) 'Pharmacogenomics: A Clinician's Primer on Emerging Technologies for Improved Patient Care', Mayo Clinic Proceedings 76: 299-309.
112. Sadée, Wolfgang (1999) 'Pharmacogenomics', British Medical Journal 319 (13 November): 1-4.
113. Salter, Brian and Mavis Jones (2002) 'Human Genetic Technologies, European Governance and the Politics of Bioethics', Nature Reviews Genetics 3(10): 808-14.
114. Schmitz, Gerd, Charalampos Aslanidis and Karl Lackner (2001) 'Pharmacogenomics: Implications for Laboratory Medicine', Clinica Chimica Acta 308: 43-53.
115. Shelling, Andrew (1997) 'Role of p53 in Drug Resistance in Ovarian Cancer', The Lancet 349 (15 March): 744-45.
116. Shook, David (2001) 'The Personalized Future of Medicine', Business Week Online 16 August 2001.
117. Steimer, Werner and Julia Potter (2002) 'Pharmacogenetic Screening and Therapeutic Drugs', Clinica Chimica Acta 315: 137-55.
118. Stern, Curt (1971) 'The Place of Genetics in Medicine', Annals of Internal Medicine 75(4): 623-29.
119. Thomas, Sandy (2001) 'Pharmacogenetics: The Ethical Context', Pharmacogenomics Journal 1(4): 239-42.
120. van Lente, Harro (1993) Promising Technology: The Dynamics of Expectations in Technological Development (Enschede: Department of Philosophy of Science and Technology University of Twente).
121. van Lente, Harro and Arie Rip (1998) 'The Rise of Membrane Technology: From Rhetorics to Social Reality', Social Studies of Science 28(2): 221-54.
122. van Ommen, G. (2000) 'Human Genetics in Health Care', European Journal of Pediatrics 159 Suppl 3: S170-72.
123. Weber, Wendell (2001) 'The Legacy of Pharmacogenetics and Potential Applications', Mutation Research 479: 1-18.
124. Weinshilboum, R. (2002) 'The Genomic Revolution and Medicine', Mayo Clinic Proceedings 77(8): 745-46.
125. Wheale, Peter, Rene von Schomberg and Peter Glasner (eds) (1998) The Social Management of Genetic Engineering (Ashgate Publishing, Ashgate).
126. Wieczorek, Stacey and Gregory Tsongalis (2001) 'Pharmacogenomics: Will It Change the Field of Medicine?', Clinica Chimica Acta 308: 1-8.
127. Wolf, C. Roland, Gillian Smith and Robert Smith (2000) 'Pharmacogenetics', British Medical Journal 320 (8 April): 987-90.
128. Wortman, Marc (2001) 'Medicine Gets Personal', MIT Technology Review January/February http://www.technologyreview.com/articles/wortman0101.asp.
129. Wyatt, Sally (2000) 'Talking About the Future: Metaphors of the Internet', in Brown et al. (2000): 109-26.